eva-1 homolog A, regulator of programmed cell deathGenealiases: FAM176A · TMEM166
Q-omics provides the consensus-scored EVA1A profile across patient tissues and cancer cell-line models. EVA1A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, EVA1A is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, EVA1A RNA expression shows 20,480 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, HNSC, and LSCC as cancer lineages where EVA1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EVA1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EVA1A survival associations across molecular data types. EVA1A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EVA1A RNA expression–survival associations across cancer types. High EVA1A expression shows unfavorable associations in MESO, LUSC, SARC and HNSC, but favorable associations in LIHC and DLBC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for EVA1A RNA expression.
This table summarizes EVA1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for EVA1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EVA1A shows lower tumor expression in KICH and LUSC and higher tumor expression in HNSC, THCA, COAD and BLCA. The HNSC box plot shows higher EVA1A RNA expression in tumor versus normal tissue (log2 FC = +2.718, t-test p < 0.001).
This table shows molecular features associated with EVA1A in patient tissues and cancer cell lines. In patient samples, EVA1A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, EVA1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and OESOPHAGUS.
